GLP-1, incretin and next-generation metabolic peptides for weight and metabolic health.
Weight Loss & Metabolic covers the best-evidenced peptide class on the site — the GLP-1 and incretin therapeutics (semaglutide, tirzepatide and the emerging dual and triple agonists) — alongside the wider metabolic-peptide landscape. This is where peptide medicine meets large, high-quality human trials, and where the compounding and shortage controversies are most consequential.
The honest, evidence-first ranking of peptides for weight loss — the GLP-1-based incretin agonists that work in human RCTs, and the 'fat-burning' GH-fragment peptides that failed in human trials.
A clinical-evidence ranking of the peptides that actually reduce visceral (belly) fat — one of the rare peptide topics with genuine Grade A human RCT proof — separating the FDA-approved and investigational incretin/GHRH drugs from the gray-market 'fat-loss' peptides that have none.
Weight Loss & MetabolicAn evidence-graded review of the peptide drugs studied for metabolic syndrome — from the Grade A incretin drugs that reverse the whole cluster to the preclinical-only compounds sold online with no completed human trial.
Weight Loss & MetabolicAn evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
Weight Loss & MetabolicA clinical-evidence ranking of the peptides marketed for insulin sensitivity and blood-sugar control — the incretin drugs that actually work in human RCTs, and the 'mitochondrial' research peptides that do not yet.
Weight Loss & MetabolicBeyond Ozempic and Wegovy: a clinical-evidence ranking of the next-generation metabolic peptides — the dual and triple incretin agonists and amylin analogues — for weight loss in 2026.
The incretin class is the strongest-evidenced group on the entire site. Semaglutide and tirzepatide are FDA-approved for obesity on the back of large randomized controlled trials (the STEP, SUSTAIN, SURMOUNT and SURPASS programs), with double-digit average weight loss and, for some agents, cardiovascular benefit. We grade these claims A. That is a sharp contrast with most other peptide categories, where the evidence is preclinical — and we flag the difference clearly.
During FDA-declared shortages, compounding pharmacies were temporarily permitted to make versions of semaglutide and tirzepatide. As the shortages resolved, that allowance was wound down, and the FDA and manufacturers warned about quality, dosing-error and counterfeit risks with non-approved compounded or gray-market product. The regulatory picture has shifted repeatedly; we date-stamp these statements and cite the FDA directly rather than relying on secondary coverage.
No. Like the rest of the site, this is informational and editorial content, not medical advice and not a sourcing guide. We explain how these peptides work, what the trials showed, how they are dosed in the label, and what the safety profile and contraindications are — but decisions about prescription metabolic medication belong with a licensed prescriber, not an article.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
